{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:26:20Z","timestamp":1764242780977,"version":"3.46.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg Cases"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder that is frequently associated with systemic lupus erythematosus (SLE). Cardiac surgery in patients with APS presents unique challenges because activated clotting time (ACT) monitoring can be unreliable, frequently yielding falsely prolonged results due to the presence of lupus anticoagulant. Although heparin concentration-based monitoring is more accurate, devices such as the Hemostasis Management System Plus have been discontinued, creating a gap in practical anticoagulation management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report two female patients with APS and severe aortic regurgitation (AR) who underwent aortic valve replacement (AVR) under cardiopulmonary bypass (CPB).<\/jats:p>\n                    <jats:p>Case 1: A 58-year-old woman with long-standing SLE and APS underwent preoperative ACT simulation using her serum mixed with a 60 U\/mL heparin solution to estimate the ACT corresponding to a heparin concentration of 3.0 U\/mL. The resulting ACT range (567\u2013708\u00a0s) guided intraoperative anticoagulation. AVR with a mechanical valve and left atrial appendage amputation (LAAA) was performed. Protamine was administered at half the calculated dose. Postoperative bleeding was transient and well controlled.<\/jats:p>\n                    <jats:p>Case 2: A 62-year-old woman with recent APS, deep vein thrombosis, and infective endocarditis underwent ACT simulation. The simulated ACT ranged from 325 to 413\u00a0s, and an intraoperative ACT target of\u2009&gt;\u2009450\u00a0s was established. AVR and LAAA were performed uneventfully with half dose protamine. No thrombotic or bleeding complications occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These cases highlight the limitations of conventional ACT monitoring in patients with APS and demonstrate the utility of individualized preoperative ACT simulation as a practical alternative. This approach allowed safe anticoagulation management without requiring advanced equipment. Reduced protamine dosing likely minimized the risk of rebound hypercoagulability, a concern in APS. Notably, despite identical heparin concentrations, ACT responses varied among the patients, underscoring the need for personalized strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preoperative ACT simulation using patient serum offers a practical, accessible, and individualized method for guiding anticoagulation therapy in patients with APS undergoing cardiac surgery. This technique may enhance perioperative safety in resource-limited settings, and warrants further validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s44215-025-00235-0","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:23:45Z","timestamp":1764242625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simulation-based activated clotting time targeting for cardiopulmonary bypass in patients with antiphospholipid syndrome: two case reports"],"prefix":"10.1186","volume":"4","author":[{"given":"Yuki","family":"Kamikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-6841","authenticated-orcid":false,"given":"Hirotaka","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"235_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"235_CR2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019\u201327.","journal-title":"Arthritis Rheum"},{"key":"235_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejcts.2007.11.004","volume":"33","author":"H Gorki","year":"2008","unstructured":"Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168\u201381.","journal-title":"Eur J Cardiothorac Surg"},{"key":"235_CR4","first-page":"16","volume":"48","author":"K Nagashima","year":"2021","unstructured":"Nagashima K, Onodera H, Numazato J, Okamoto R, Tokuse R, Shimizu D, et al. Examination of optimal target heparin concentration during cardiopulmonary bypass in antiphospholipid antibody syndrome. Jpn J Extra-Corporeal Technology. 2021;48:16\u201324.","journal-title":"Jpn J Extra-Corporeal Technology"},{"key":"235_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1051\/ject\/202153046","volume":"53","author":"K Ural","year":"2021","unstructured":"Ural K, Edelson J. Antiphospholipid syndrome and cardiac bypass: the careful balance between clotting and bleeding. J Extra Corpor Technol. 2021;53:46\u20139.","journal-title":"J Extra Corpor Technol"},{"key":"235_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1213\/ANE.0000000000002613","volume":"126","author":"L Shore-Lesserson","year":"2018","unstructured":"Shore-Lesserson L, Baker RA, Ferraris VA, Greilich PE, Fitzgerald D, Roman P, et al. The society of thoracic surgeons, the society of cardiovascular anesthesiologists, and the American society of extracorporeal technology: clinical practice guidelines-anticoagulation during cardiopulmonary bypass. Anesth Analg. 2018;126:413\u201324.","journal-title":"Anesth Analg"},{"key":"235_CR7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/00000539-200005000-00017","volume":"90","author":"CJ East","year":"2000","unstructured":"East CJ, Clements F, Mathew J, Slaughter TF. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg. 2000;90:1098\u2013101.","journal-title":"Anesth Analg"},{"key":"235_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10047-018-1032-7","volume":"21","author":"T Seki","year":"2018","unstructured":"Seki T, Shingu Y, Sugiki H, Wakasa S, Katoh H, Ooka T, et al. Anticoagulation management during cardiopulmonary bypass in patients with antiphospholipid syndrome. J Artif Organs. 2018;21:363\u20136.","journal-title":"J Artif Organs"},{"key":"235_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0022-5223(05)80008-X","volume":"110","author":"GJ Despotis","year":"1995","unstructured":"Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, Goodnough LT, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46\u201354.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"235_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/00000542-199910000-00031","volume":"91","author":"GJ Despotis","year":"1999","unstructured":"Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999;91:1122\u201351.","journal-title":"Anesthesiology"}],"container-title":["General Thoracic and Cardiovascular Surgery Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-025-00235-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44215-025-00235-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-025-00235-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:23:46Z","timestamp":1764242626000},"score":1,"resource":{"primary":{"URL":"https:\/\/gtcscases.biomedcentral.com\/articles\/10.1186\/s44215-025-00235-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1186\/s44215-025-00235-0","relation":{},"ISSN":["2731-6203"],"issn-type":[{"value":"2731-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki of 2019 and its later version. Informed consent or a substitute was obtained from all patients for inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}